Botco.ai's Co-Founder & Executive Chairman, Anu Shukla says, 'Instant' is the new mantra

Media 7 | November 15, 2021

Anu Shukla, Co- Founder & Executive Chairman at Botco.ai explores the latest features on Botco.ai 2.0 and how it helps marketers in health and wellness verticals make more personalized, analytical and actionable insight-driven campaigns. Read on to find out about the biggest challenges in the current COVID-19 influenced product marketing landscape.

The millennial and other customer segments have no patience for long hold times, pointing and clicking through endless web pages and trying to read long manuals or 100s of FAQs.

MEDIA 7: Could you please take us through your 20 years of high-tech industry experience?
ANU SHUKLA:
I began my career as a marketing manager in a passive electronic components firm in Silicon Valley. After that, I worked in several software companies as the VP of marketing and Products and all of them went public or were acquired. I felt like I was ready to take the leap to my own venture and I started a company called Rubric which was an early pioneer in marketing automation software and was acquired within 18 months for about $400 million! Some of the features that are now standard fare in a marketer’s toolbox were invented by us like lead nurturing, close loop marketing, and email drip campaigns. After that, I started several companies in AdTech, MarTech, and payments/loyalty. My 3 exits include Rubric, MyBuys, and Tapjoy, for over a billion dollars in enterprise value. I am currently an Angel investor, a venture partner with elevate.vc – supporting underrepresented black, LatinX, and female founders and also co-founded and the executive Chair of Botco.ai. This is our new entrée into marketing automation applying AI and conversational marketing techniques to enhance outcomes for our enterprise health and wellness customers. Other details about my journey can be found here : https://www.linkedin.com/in/anushukla/


M7: Botco.ai has partnered with STChealth. What does this partnership offer new to the table for your clients and customers?
AS:
STC Health is a customer of ours – they provide mass immunization records and have partnerships with all the states. They use our AI chat platform to answer thousands of queries and requests for immunization records from consumers, schools etc. Our platform enables them to provide a valuable service for the general health and safety of the country.

Read More: Khronos Founder Daniel Englebretson predicts the rise of AI to result in consumers expecting more tailored experiences 


Ecommerce has become even bigger, remote work is a necessity, and virtual collaboration is needed.



M7: What is new in Botco.ai’s conversational chat platform Version 2.0?
AS:
Botco.ai 2.0 is rich in features and functionality that are needed for marketing applications in health and wellness verticals. They can be divided into 3 pillars of personalization, AI/NLP and actionable insights, and analytics dashboard. Unlike the do it yourself chatbots, Botco.ai has functionality geared for marketing applications – such as referral code tracking that can initiate a chat knowing which ad campaign or banner you are coming from, our new AI algorithms can analyze a vast amount of texts and create the questions and answers base from it in hours not weeks, as well as new sentiment analysis that can make the bot aware of negative or other sentiments in the responses. And last but not the least, our dashboard can analyze the conversations occurring and present insights such as what product or feature is being requested, what times of day, and what this means in context. Finally, we are always bringing out new integrations with EHR, CRM systems, and other useful and strategic products such as VerifyTx that allow for verification of insurance benefits from a chat interface on a website.


M7: What do you see as the most noticeable change right now happening in the workforce, encouraged by the rise of digital technologies?
AS:
The rise of digital technologies combined with the effects of the pandemic have accelerated the adoption of virtual and digital technologies in industries that have been slow adopters like healthcare. Ecommerce has become even bigger, remote work is a necessity, and virtual collaboration is needed. Botco.ai strives to provide a platform to enable the leap to a digital, virtual world – I guess we could call ourselves a good citizen of the evolving health and wellness metaverse!

Read More: 'I believe in servant leadership,' says Don White, CEO and Co-founder at Satisfi Labs


The rise of digital technologies combined with the effects of the pandemic have accelerated the adoption of virtual and digital technologies in industries that have been slow adopters like healthcare.



M7: What do you believe are the top three product marketing challenges in the post COVID-19 era?
AS:
We live in an on-demand world where “instant” is the new mantra. The millennial and other customer segments have no patience for long hold times, pointing and clicking through endless web pages and trying to read long manuals or 100s of FAQs. The top challenge for marketers is to engage with customers in a meaningful, frictionless way and get them the precise information they are looking for before they jump to another site in about 57 seconds ( studies show). AI/chat is one of the best ways to do that through intelligently layered conversational interfaces over static web pages. The second challenge is to make sense of vast amounts of data that the systems are churning out in an actionable way, and finally to do this in a world where remote and virtual is the new normal and budgets have probably been flat.


M7: What is your advice to young women entrepreneurs of today?
AS:
I would encourage young women to really know and be passionate about the ventures they pursue, to prepare and do the research, to network and build a stable of mentors and funders, and to take the leap without fear of failure because you will learn and build on the failures.

ABOUT BOTCO.AI

Botco.ai is a conversational marketing platform enabling meaningful and intelligent conversations between businesses and their customers. Botco.ai is a HIPAA-compliant platform enabling meaningful and intelligent conversations between providers and consumers. Botco.ai is a fully-automated, AI-powered marketing chat solution that can be implemented at scale. The company offers industry-leading authoring, webchat, and AI machine-learning capabilities to quickly and effectively convert more customers. Botco.ai’s Integrated Analytics Dashboard provides a comprehensive view of chat campaigns across multiple channels such as web and Facebook Messenger. The API-based interface can be used to transfer leads, transcripts, and data into enterprise sales and marketing automation products like Salesforce, Hubspot, Adobe Marketing Cloud, and Zoho. For more information, visit Botco.ai.

More THOUGHT LEADERS

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant. Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego. MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft? CRAIG MISRACH: I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character! I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period. I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up. I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively. I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world. The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego. I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner. M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this? CM: Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including: 1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers. 2. Providing in-person demonstrations where we captured testimonials of use and purchase interest. 3. Creating video content of UpLyft in use (seeing is believing). 4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments. With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them. ...

Read More

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant. Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego. MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft? CRAIG MISRACH: I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character! I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period. I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up. I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively. I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world. The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego. I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner. M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this? CM: Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including: 1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers. 2. Providing in-person demonstrations where we captured testimonials of use and purchase interest. 3. Creating video content of UpLyft in use (seeing is believing). 4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments. With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them. ...

Read More

Related News

Health Technology

Crothall and Beyond Clean Revolutionize Sterile Processing Education

Beyond Clean | September 07, 2023

Two prominent entities in the sterile processing industry, Crothall Healthcare and Beyond Clean, have entered into a strategic partnership to develop an innovative educational curriculum specially designed for sterile processing professionals serving in hospitals throughout the United States. This partnership leverages both organizations' collective wealth of knowledge and extensive experience to empower sterile processing professionals with state-of-the-art expertise, enhance patient safety, and elevate the overall benchmarks for sterile processing industry-wide. Afif Escheik, BA, CHL, CER, CIS, CRCST, CST, Regional Director of Operations at Crothall Healthcare, expressed that this partnership will enhance the company's capacity to provide sterile processing professionals with the educational tools necessary to meet and exceed industry standards, reduce errors, and optimize productivity. Crothall's track record of achievement in the field of sterile processing has been founded upon its stringent, data-centric methodologies, which have led to a remarkable enhancement in audit compliance of nearly 90%, a substantial reduction in process errors of up to 50%, and significant productivity gains of up to 62%. Through this collaboration, Crothall intends to incorporate these invaluable insights into developing the forthcoming curriculum. Hank Balch, Founder and President of Beyond Clean, remarked that this partnership will help elevate the standard of sterile processing in the United States, significantly impacting patient safety and quality of service. The collaborative curriculum is adaptable for various care settings, promoting sustainable, high-value care, enhancing patient safety, and reducing errors across the healthcare organization. This partnership signifies a significant step towards a safer and more efficient future in surgical services. About Crothall Healthcare With more than three decades of experience in the healthcare sector, Crothall Healthcare is the foremost provider of patient-centered support services, offering comprehensive solutions tailored to diverse care settings. Its sterile processing services integrate extensive healthcare expertise, clinical rigor, and industry best practices to deliver efficient and highly effective services. About Beyond Clean Beyond Clean is a global expert in sterilizing educational content. The company's unwavering commitment to sterile processing motivates it to empower frontline professionals with essential knowledge, education, and steadfast assistance. It also enables them to uphold impeccable standards and ensure the continuous cleanliness of all instruments.

Read More

Health Technology

TeleVox Secures Odeza's Patient Engagement Unit from Ensemble Health

TeleVox | September 11, 2023

TeleVox and Ensemble will provide Ensemble's clients with an all-encompassing healthcare solution, from patient acquisition to post-discharge care. This announcement is yet another significant milestone in TeleVox's continuous rapid growth and expansion journey. This acquisition underscores TeleVox's commitment to strengthening its presence in the healthcare sector as it integrates Odeza's patient engagement business. TeleVox, a distinguished provider of state-of-the-art omnichannel digital patient engagement technology, has completed a significant acquisition by owning the Odeza patient engagement business from Ensemble Health Partners (Ensemble). Ensemble, recognized as a preeminent force in revenue cycle management, specializes in delivering its services to various healthcare institutions, including hospitals, health systems, and physician practices. TeleVox and Ensemble are committed to extending the reach and accessibility of TeleVox's cutting-edge technology to Ensemble's existing customer base. This strategic endeavor aims to deliver healthcare providers an all-encompassing solution that seamlessly caters to a broad spectrum of healthcare requirements, commencing with the initial patient acquisition phase and extending throughout the entirety of the patient journey. This comprehensive approach encompasses not only the discharge process but extends into subsequent phases of aftercare and beyond, equipping healthcare institutions with the essential tools and resources to optimize patient engagement, streamline operational workflows, and elevate the overall quality of care delivery. Additionally, this move positions TeleVox to enhance its capabilities further in providing innovative solutions, enabling healthcare providers to engage with patients in a more comprehensive and technologically advanced manner, ultimately advancing the healthcare industry. Vik Krishnan, President of TeleVox, expressed his welcome to Odeza joining the TeleVox family and highlighted that the acquisition of Odeza's patient engagement business aligns with TeleVox's longstanding commitment to tailored communication solutions for enhancing the patient experience, solidifying TeleVox's position as an industry leader. He also emphasized that making their patient engagement solutions accessible to Ensemble's extensive customer base will enable more healthcare providers to deliver exceptional patient care. Judson Ivy, Founder, President and CEO of Ensemble Health Partners, remarked, "This partnership strengthens each of our positions in the healthcare industry and delivers unmatched value to our customers." Meanwhile, the company unveiled Iris, an AI-powered omnichannel conversational virtual assistant tailored for healthcare providers, in April. The introduction of an automated reputation management solution in the month that followed this significant development gave hospitals, health systems, and physician practices the ability to manage and improve their online presence effectively.

Read More

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Read More

Health Technology

Crothall and Beyond Clean Revolutionize Sterile Processing Education

Beyond Clean | September 07, 2023

Two prominent entities in the sterile processing industry, Crothall Healthcare and Beyond Clean, have entered into a strategic partnership to develop an innovative educational curriculum specially designed for sterile processing professionals serving in hospitals throughout the United States. This partnership leverages both organizations' collective wealth of knowledge and extensive experience to empower sterile processing professionals with state-of-the-art expertise, enhance patient safety, and elevate the overall benchmarks for sterile processing industry-wide. Afif Escheik, BA, CHL, CER, CIS, CRCST, CST, Regional Director of Operations at Crothall Healthcare, expressed that this partnership will enhance the company's capacity to provide sterile processing professionals with the educational tools necessary to meet and exceed industry standards, reduce errors, and optimize productivity. Crothall's track record of achievement in the field of sterile processing has been founded upon its stringent, data-centric methodologies, which have led to a remarkable enhancement in audit compliance of nearly 90%, a substantial reduction in process errors of up to 50%, and significant productivity gains of up to 62%. Through this collaboration, Crothall intends to incorporate these invaluable insights into developing the forthcoming curriculum. Hank Balch, Founder and President of Beyond Clean, remarked that this partnership will help elevate the standard of sterile processing in the United States, significantly impacting patient safety and quality of service. The collaborative curriculum is adaptable for various care settings, promoting sustainable, high-value care, enhancing patient safety, and reducing errors across the healthcare organization. This partnership signifies a significant step towards a safer and more efficient future in surgical services. About Crothall Healthcare With more than three decades of experience in the healthcare sector, Crothall Healthcare is the foremost provider of patient-centered support services, offering comprehensive solutions tailored to diverse care settings. Its sterile processing services integrate extensive healthcare expertise, clinical rigor, and industry best practices to deliver efficient and highly effective services. About Beyond Clean Beyond Clean is a global expert in sterilizing educational content. The company's unwavering commitment to sterile processing motivates it to empower frontline professionals with essential knowledge, education, and steadfast assistance. It also enables them to uphold impeccable standards and ensure the continuous cleanliness of all instruments.

Read More

Health Technology

TeleVox Secures Odeza's Patient Engagement Unit from Ensemble Health

TeleVox | September 11, 2023

TeleVox and Ensemble will provide Ensemble's clients with an all-encompassing healthcare solution, from patient acquisition to post-discharge care. This announcement is yet another significant milestone in TeleVox's continuous rapid growth and expansion journey. This acquisition underscores TeleVox's commitment to strengthening its presence in the healthcare sector as it integrates Odeza's patient engagement business. TeleVox, a distinguished provider of state-of-the-art omnichannel digital patient engagement technology, has completed a significant acquisition by owning the Odeza patient engagement business from Ensemble Health Partners (Ensemble). Ensemble, recognized as a preeminent force in revenue cycle management, specializes in delivering its services to various healthcare institutions, including hospitals, health systems, and physician practices. TeleVox and Ensemble are committed to extending the reach and accessibility of TeleVox's cutting-edge technology to Ensemble's existing customer base. This strategic endeavor aims to deliver healthcare providers an all-encompassing solution that seamlessly caters to a broad spectrum of healthcare requirements, commencing with the initial patient acquisition phase and extending throughout the entirety of the patient journey. This comprehensive approach encompasses not only the discharge process but extends into subsequent phases of aftercare and beyond, equipping healthcare institutions with the essential tools and resources to optimize patient engagement, streamline operational workflows, and elevate the overall quality of care delivery. Additionally, this move positions TeleVox to enhance its capabilities further in providing innovative solutions, enabling healthcare providers to engage with patients in a more comprehensive and technologically advanced manner, ultimately advancing the healthcare industry. Vik Krishnan, President of TeleVox, expressed his welcome to Odeza joining the TeleVox family and highlighted that the acquisition of Odeza's patient engagement business aligns with TeleVox's longstanding commitment to tailored communication solutions for enhancing the patient experience, solidifying TeleVox's position as an industry leader. He also emphasized that making their patient engagement solutions accessible to Ensemble's extensive customer base will enable more healthcare providers to deliver exceptional patient care. Judson Ivy, Founder, President and CEO of Ensemble Health Partners, remarked, "This partnership strengthens each of our positions in the healthcare industry and delivers unmatched value to our customers." Meanwhile, the company unveiled Iris, an AI-powered omnichannel conversational virtual assistant tailored for healthcare providers, in April. The introduction of an automated reputation management solution in the month that followed this significant development gave hospitals, health systems, and physician practices the ability to manage and improve their online presence effectively.

Read More

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Read More